Mural Oncology
Mural Oncology is dedicated to transforming cancer immunotherapy through innovative protein engineering. Their mission is to develop and deliver new medicines that increase the number of patients benefiting from immunotherapy, focusing on cytokine-based therapies for difficult-to-treat cancers. They leverage their expertise in cytokine biology and immune cell modulation to create first- and best-in-class immunotherapies, aiming to provide meaningful clinical benefits across a wide range of cancers.
Industries
Nr. of Employees
medium (51-250)
Mural Oncology
Patents
Compositions and methods for subcutaneous administration of cancer immunotherapy
US-11980652-B2
View DetailsImmunomodulatory IL-2 agents in combination with immune checkpoint inhibitors
US-11945870-B2
View Details
Compositions and methods for subcutaneous administration of cancer immunotherapy
US-11980652-B2
View DetailsImmunomodulatory IL-2 agents in combination with immune checkpoint inhibitors
US-11945870-B2
View DetailsProducts
Engineered IL-2 variant immunotherapy (clinical lead)
An engineered interleukin-2 variant designed for selective immune modulation and evaluated in early- and late-stage clinical trials.
Half-life–extended IL-18 variant resistant to endogenous binding protein (preclinical)
An IL-18 variant engineered for extended circulation time and reduced inhibition by endogenous binding proteins to enhance therapeutic potential.
Tumor-targeted split IL-12 subunit therapy (preclinical)
Split IL-12 subunits delivered via tumor-targeting modalities that preferentially self-assemble at the tumor site to limit systemic exposure.
Engineered IL-2 variant immunotherapy (clinical lead)
An engineered interleukin-2 variant designed for selective immune modulation and evaluated in early- and late-stage clinical trials.
Half-life–extended IL-18 variant resistant to endogenous binding protein (preclinical)
An IL-18 variant engineered for extended circulation time and reduced inhibition by endogenous binding proteins to enhance therapeutic potential.
Tumor-targeted split IL-12 subunit therapy (preclinical)
Split IL-12 subunits delivered via tumor-targeting modalities that preferentially self-assemble at the tumor site to limit systemic exposure.
Services
Design and run multi-phase oncology clinical trials, including combination therapy studies and dosing schedule optimization.
Evaluation and administration of compassionate use requests for investigational oncology therapies prior to approval.
Preparation and distribution of preclinical and clinical findings through peer-reviewed journals and scientific meetings.
Point of contact and engagement for potential development collaborations, media, and investor relations.
Design and run multi-phase oncology clinical trials, including combination therapy studies and dosing schedule optimization.
Evaluation and administration of compassionate use requests for investigational oncology therapies prior to approval.
Preparation and distribution of preclinical and clinical findings through peer-reviewed journals and scientific meetings.
Point of contact and engagement for potential development collaborations, media, and investor relations.
Expertise Areas
- Cytokine-based immunotherapy development
- Protein engineering for biologics
- Preclinical oncology models and efficacy testing
- Clinical trial design and management (Phases 1–3)
Key Technologies
- Protein engineering
- Cytokine variant design
- Half-life extension techniques
- Binding-protein resistance engineering
News & Updates
April 15, 2025 - Mural Oncology announces plans to explore strategic alternatives.
March 25, 2025 - Update on the Phase 3 ARTISTRY-7 trial.
March 11, 2025 - Financial results and upcoming milestones.
Publication in Journal for ImmunoTherapy in Cancer (JITC), November 2023.
Presented at Society for Immunotherapy of Cancer (SITC), November 2024.
Presented at Society for Immunotherapy of Cancer (SITC), November 2024.
April 15, 2025 - Mural Oncology announces plans to explore strategic alternatives.
March 25, 2025 - Update on the Phase 3 ARTISTRY-7 trial.
March 11, 2025 - Financial results and upcoming milestones.
Publication in Journal for ImmunoTherapy in Cancer (JITC), November 2023.
Presented at Society for Immunotherapy of Cancer (SITC), November 2024.
Presented at Society for Immunotherapy of Cancer (SITC), November 2024.